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T-cell based immunotherapy applications have recently drawn great interest and notoriety due to their clinical 
potential as next-generation life-saving therapies for cancer patients. Generation of sufficient, desired T-cell 
populations is an essential task for the successful development of T-cell based immunotherapy, requiring an 
effective, scalable, and consistent ex vivo manufacturing process.  A suitable chemically-defined (CD), animal-
component-free (ACF) T-cell basal medium would significantly foster the establishment of such a process.  
Presented in this study is the development of a CD, ACF T-cell basal culture medium that is scalable and 
suitable for the manufacture of adoptive T-cell therapy products. A ‘quality of design’ approach coupled with 
spent media analysis was utilized to examine the effects of various key media compositions such as amino 
acids, vitamins, minerals, and lipids on activated human peripheral blood-derived T cells proliferation.  The 
resulting CD, ACF basal expansion medium was comparable or superior to media containing serum (RPMI + 
10% FBS) or serum-derived human albumin in the culture of both CD4+ and CD8+ T-cell populations.  Further 
supplementation with proper cytokine combinations verified and demonstrated the CD, ACF basal media’s 
performance in effectively supporting the derivation of major T helper subsets, such as Th1, Th2 and Treg, from 
naïve CD4+ T cells.  In addition to its utility in static culture conditions using T-flasks, the CD, ACF basal 
medium was subsequently evaluated for its potential application in other commonly used expansion vehicles 
including spinner flasks, culture bags, and G-Rex plate systems.  A total expansion of 50 and 80-fold was 
achieved through the G-Rex plate and culture bag systems, respectively, when cultures were maintained for up 
to 14 days accompanied by a single media replenishment event suggesting the potential for even higher yields 
with further optimization and feeding steps.  In all cases, the CD, ACF medium delivered the best growth profile 
while maintaining high viability and desired T-cell phenotypes (e.g. % of CD62L+ cells).  The evaluation results 
demonstrate the improved performance delivered by the CD, ACF medium over serum-containing media and its 
suitability for use in the manufacture of adoptive T-cell therapy products.  
 
